BESPONSA (inotuzumab ozogamicin)
ANTINEOPLAS-CD22 SPECIFIC ANTIBODY/CYTOTOXIC ANTIBIOTIC CONJ · CD22 POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
Wyeth Pharmaceutical
Drug class
Antineoplas-CD22 Specific Antibody/Cytotoxic Antibiotic Conj
The phrase "Antineoplas-CD22 Specific Antibody/Cytotoxic Antibiotic Conj" is an administrative formulary and compendia classification descriptor rather than a standard regulatory or pharmacology category. Read more about Antineoplas-CD22 Specific Antibody/Cytotoxic Antibiotic Conj
1 drugs in this class 1 manufacturers
Drugs in Antineoplas-CD22 Specific Antibody/Cytotoxic Antibiotic Conj
Filter & compare in the drug finder →
Opens the drug finder with Antineoplas-CD22 Specific Antibody/Cytotoxic Antibiotic Conj preselected. Add indication or manufacturer filters there.
The phrase "Antineoplas-CD22 Specific Antibody/Cytotoxic Antibiotic Conj" is an administrative formulary and compendia classification descriptor rather than a standard regulatory or pharmacology category.
It identifies antibody-drug conjugates (ADCs) in which a monoclonal antibody targeting the B-cell antigen CD22 is covalently linked to a potent cytotoxic antitumor antibiotic payload, exemplified by inotuzumab ozogamicin.
Mechanistically, the antibody binds cell-surface CD22, undergoes receptor-mediated endocytosis, and releases the cytotoxic antibiotic payload—such as calicheamicin—inside the cell to induce double-stranded DNA cleavage and apoptotic death.
Therapeutically, this category is indicated for hematologic malignancies, primarily relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL).
-
iehp.org
The phrase "Antineoplas-CD22 Specific Antibody/Cytotoxic Antibiotic Conj" is an administrative formulary and compendia classification descriptor rather than a standard regulatory or pharmacology category It identifies antibody-drug conjugates (ADCs) in which a monoclonal antibody targeting the B-cell antigen CD22 is covalently linked to a potent cytotoxic antitumor antibiotic payload, exemplified by inotuzumab ozogamicin
-
memorialcareselecthealthplan.org
The phrase "Antineoplas-CD22 Specific Antibody/Cytotoxic Antibiotic Conj" is an administrative formulary and compendia classification descriptor rather than a standard regulatory or pharmacology category
-
biopharmaspec.com
It identifies antibody-drug conjugates (ADCs) in which a monoclonal antibody targeting the B-cell antigen CD22 is covalently linked to a potent cytotoxic antitumor antibiotic payload, exemplified by inotuzumab ozogamicin Mechanistically, the antibody binds cell-surface CD22, undergoes receptor-mediated endocytosis, and releases the cytotoxic antibiotic payload—such as calicheamicin—inside the cell to induce double-stranded DNA cleavage and apoptotic death Therapeutically, this category is indica...
-
bocsci.com
It identifies antibody-drug conjugates (ADCs) in which a monoclonal antibody targeting the B-cell antigen CD22 is covalently linked to a potent cytotoxic antitumor antibiotic payload, exemplified by inotuzumab ozogamicin Therapeutically, this category is indicated for hematologic malignancies, primarily relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL)
-
cancer.gov
Mechanistically, the antibody binds cell-surface CD22, undergoes receptor-mediated endocytosis, and releases the cytotoxic antibiotic payload—such as calicheamicin—inside the cell to induce double-stranded DNA cleavage and apoptotic death
-
accp1.org
Mechanistically, the antibody binds cell-surface CD22, undergoes receptor-mediated endocytosis, and releases the cytotoxic antibiotic payload—such as calicheamicin—inside the cell to induce double-stranded DNA cleavage and apoptotic death
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.